Contents

Search

peramivir (Rapivab)

FDA-approved Dec 2014 Indications: - uncomplicated influenza in adults with symptoms of <= 2 days' duration Dosage: - 600 mg intravenous infusion (once) Adverse effects: - diarrhea (> 2%) - Stevens-Johnson syndrome. erythema multiforme Mechanism of action: - sialic acid analog, selective inhibitor of neuraminidases produced by influenza A virus & influenza B virus [2] Notes: - investigational drug, emergency use authorization during swine flu epidemic of 2009

General

antiviral agent

Database Correlations

PUBCHEM correlations

References

  1. FDA MedWatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm187814.htm
  2. Kohno S et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010 Nov; 54:4568 PMID: 20713668
  3. FDA News Release. December 22, 2014 FDA approves Rapivab to treat flu infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm
  4. Peramivir prescribing information http://rapivab.com/wp-content/uploads/2014/12/Rapivab-PI.pdf